Oestrogen receptor β: What it means for patients with breast cancer

Valerie Speirs; Pauline J. Carder; Sally Lane; David Dodwell; Mark R.J. Lansdown; Andrew M. Hanby

doi:10.1016/S1470-2045(04)01413-5

Oestrogen receptor β: What it means for patients with breast cancer

Valerie Speirs^*, Pauline J. Carder, Sally Lane, David Dodwell, Mark R.J. Lansdown, Andrew M. Hanby

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

116 Citations (Scopus)

Abstract

Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

Original language	English
Pages (from-to)	174-181
Number of pages	8
Journal	Lancet Oncology
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(04)01413-5
Publication status	Published - 1 Mar 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(04)01413-5

Cite this

@article{cd04ebf211164671a54cce0974aea40f,

title = "Oestrogen receptor β: What it means for patients with breast cancer",

abstract = "Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.",

author = "Valerie Speirs and Carder, {Pauline J.} and Sally Lane and David Dodwell and Lansdown, {Mark R.J.} and Hanby, {Andrew M.}",

year = "2004",

month = mar,

day = "1",

doi = "10.1016/S1470-2045(04)01413-5",

language = "English",

volume = "5",

pages = "174--181",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - Oestrogen receptor β

T2 - What it means for patients with breast cancer

AU - Speirs, Valerie

AU - Carder, Pauline J.

AU - Lane, Sally

AU - Dodwell, David

AU - Lansdown, Mark R.J.

AU - Hanby, Andrew M.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

AB - Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=1342330354&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(04)01413-5

DO - 10.1016/S1470-2045(04)01413-5

M3 - Review article

C2 - 15003201

AN - SCOPUS:1342330354

VL - 5

SP - 174

EP - 181

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 3

ER -

Oestrogen receptor β: What it means for patients with breast cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this